TY  - JOUR
AU  - Hidalgo-Tenorio, Carmen
AU  - Pasquau, Juan
AU  - Vinuesa, David
AU  - Ferra, Sergio
AU  - Terrón, Alberto
AU  - SanJoaquín, Isabel
AU  - Payeras, Antoni
AU  - Martínez, Onofre Juan
AU  - López-Ruz, Miguel Ángel
AU  - Omar, Mohamed
AU  - de la Torre-Lima, Javier
AU  - López-Lirola, Ana
AU  - Palomares, Jesús
AU  - Blanco, José Ramón
AU  - Montero, Marta
AU  - García-Vallecillos, Coral
PY  - 2022
DO  - 10.3390/v14030524
UR  - http://hdl.handle.net/10668/21599
T2  - Viruses
AB  - Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on...
LA  - en
KW  - DOLAVI
KW  - HIV
KW  - dolutegravir
KW  - lamivudine
KW  - real-world data
KW  - Adult
KW  - Anti-HIV Agents
KW  - Drug Therapy, Combination
KW  - Female
KW  - HIV Infections
KW  - HIV Seropositivity
KW  - HIV-1
KW  - Heterocyclic Compounds, 3-Ring
KW  - Homosexuality, Male
KW  - Humans
KW  - Lamivudine
KW  - Male
KW  - Oxazines
KW  - Piperazines
KW  - Pyridones
KW  - Sexual and Gender Minorities
KW  - Viral Load
TI  - DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
TY  - research article
VL  - 14
ER  -